597 related articles for article (PubMed ID: 25169850)
21. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
22. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
23. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
24. Novel therapeutic approaches for targeting tumor angiogenesis.
Linkous AG; Yazlovitskaya EM
Anticancer Res; 2012 Jan; 32(1):1-12. PubMed ID: 22213282
[TBL] [Abstract][Full Text] [Related]
25. The role of IL-1β in the early tumor cell-induced angiogenic response.
Carmi Y; Dotan S; Rider P; Kaplanov I; White MR; Baron R; Abutbul S; Huszar M; Dinarello CA; Apte RN; Voronov E
J Immunol; 2013 Apr; 190(7):3500-9. PubMed ID: 23475218
[TBL] [Abstract][Full Text] [Related]
26. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
28. Pathways mediating VEGF-independent tumor angiogenesis.
Ferrara N
Cytokine Growth Factor Rev; 2010 Feb; 21(1):21-6. PubMed ID: 20005148
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor and its inhibitors.
Verheul HM; Pinedo HM
Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
33. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis in cancer - general pathways and their therapeutic implications.
Dimova I; Popivanov G; Djonov V
J BUON; 2014; 19(1):15-21. PubMed ID: 24659637
[TBL] [Abstract][Full Text] [Related]
35. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
36. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
37. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Mittal K; Ebos J; Rini B
Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295
[TBL] [Abstract][Full Text] [Related]
39. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
40. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
